Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?

Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?

This mini review explores the increasing prevalence of obesity in type 1 diabetes (T1D) and the challenges patients face in achieving optimal glycemic control with current treatments. It discusses the evidence supporting the use of glucagon-like peptide-1 receptor agonists (GLP-1RA) as potential adj...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ortal Resnick, Fernando Bril, Giovanna Beauchamp
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Endocrinology
Subjects:	obesity adiposity insulin resistance overweight weight loss
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2024.1520313/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review
by: Aleksander Jentkiewicz, et al.
Published: (2025-02-01)

The impact of weight loss interventions on disordered eating symptoms in people with overweight and obesity: a systematic review & meta-analysisResearch in context
by: Elena Tsompanaki, et al.
Published: (2025-02-01)

Editorial: Weighing the impact of being overweight on female reproductive function and fertility
by: Theocharis Koufakis, et al.
Published: (2025-02-01)

Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus
by: Alexander C. Martins, et al.
Published: (2024-04-01)

Prevalence and association of non-alcoholic fatty liver disease and insulin resistance among non-diabetic obese, overweight, and metabolically obese normal-weight adult patients attending at a tertiary care hospital in Eastern India
by: Samik Pramanik, et al.
Published: (2025-02-01)

Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges
by: Francisco Westermeier, et al.
Published: (2025-01-01)

OBESITY AS A SPECIFIC OBSTACLE SUSTAINABLE SOCIAL AND ECONOMIC DEVELOPMENT
by: S. Kuzin, et al.
Published: (2016-07-01)

Is Weight Loss the Main Driver for A1C Improvement by Glucagon‐Like Peptide 1 (GLP‐1) Receptor Agonists? A 2.5‐Year Analysis in Real‐World Clinical Practice
by: Marwa Al‐Badri, et al.
Published: (2025-01-01)

Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence
by: Srikanth Krishnan, et al.
Published: (2025-01-01)

Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis
by: Noritaka Sawada, et al.
Published: (2020-01-01)

Visceral adipose tissue area and proportion provide distinct reflections of cardiometabolic outcomes in weight loss; pooled analysis of MRI-assessed CENTRAL and DIRECT PLUS dietary randomized controlled trials
by: Hadar Klein, et al.
Published: (2025-02-01)

Disorders of Adipose Tissue and Lipodystrophies: Causes, Consequences, and Treatment Perspectives
by: Rosińska Kamila Rosińska, et al.
Published: (2025-02-01)

Lack of adipocyte FAM20C improves whole body glucose homeostasis
by: Liping Deng, et al.
Published: (2024-11-01)

Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity
by: Andrew Overholser, et al.
Published: (2025-02-01)

Prevalence and Associated Risk Factors of Childhood Obesity and Overweight in Erbil City, Kurdistan, Iraq: A Household Survey
by: Sabah Shareef Mohammed, et al.
Published: (2024-03-01)

Weight Loss and the Older Adult: Risks and Benefits
by: Wendy Gans, et al.
Published: (2020-09-01)

Weight Loss and the Older Adult: Risks and Benefits
by: Wendy Gans, et al.
Published: (2020-09-01)

The association of dietary approaches to stop hypertension measured by the food frequency questionnaire with metabolic syndrome and some inflammatory biomarkers in adolescents with obesity: a case-control study
by: Maryam Behrooz, et al.
Published: (2025-01-01)

Perioperative glucagon-like peptide-1 receptor agonists–induced gastroparesis – Is gastric ultrasound the answer?
by: Suryakumar Narayanasamy, et al.
Published: (2024-09-01)

Obesity-induced mesenteric PVAT remodelling is sexually dimorphic, but not driven by ovarian hormones
by: Lisa Ivatt, et al.
Published: (2025-01-01)

Engaging health system, service and consumer representatives in the co-design of a multi-criteria decision-making framework for commissioning overweight and obesity programs and services
by: Laura Thomas, et al.
Published: (2025-01-01)

PREOPERATIVE HOSPITALIZATION AS A BRIDGING STRATEGY FOR WEIGHT LOSS IN PATIENTS WITH BODY MASS INDEX = 50 KG/M2 WHO ARE CANDIDATES FOR BARIATRIC SURGERY
by: Renata Ramos Severo, et al.
Published: (2025-01-01)

A review on mechanisms of action of bioactive peptides against glucose intolerance and insulin resistance
by: Forough Jahandideh, et al.
Published: (2022-11-01)

The BET inhibitor JQ1 targets fat metabolism and counteracts obesity
by: Claudia Fornelli, et al.
Published: (2025-02-01)

Trends and determinants of obesity among ever-married women aged 15–49 in India: insights from National Family Health Surveys (NFHS 1998–2021)
by: Aditya Singh, et al.
Published: (2025-02-01)

Intermittent fasting: Effectiveness and safety. A review
by: Marina V. Altashina, et al.
Published: (2024-12-01)

One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
by: Hirotaka Watada
Published: (2025-02-01)

The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis
by: Hanieh Radkhah, et al.
Published: (2025-02-01)

Medicines for the management of overweight and obesity: A systematic review with network meta-analysis
by: Gabriela Masiero Marcon, et al.
Published: (2025-01-01)

Associations of early life per- and polyfluoroalkyl substances (PFAS) exposure with body mass index and risk of overweight or obesity at age 2–18 years: Mixture analysis in the prospective Boston Birth Cohort
by: Zeyu Li, et al.
Published: (2025-01-01)

Effect of glucagon-like peptide-1 receptor agonists in osteoarthritis: A systematic review of pre-clinical and human studies
by: Jacinta Cheng, et al.
Published: (2025-03-01)

Overweight and obesity among adolescents: health-conscious behaviours, acceptance, and the health behaviours of their parents
by: Anna Lewandowska, et al.
Published: (2025-02-01)

Physical behaviours during pregnancy may alter the association of maternal insulin sensitivity with neonatal adiposity: a prospective pre-birth cohort of mother-child pairs
by: Piraveena Satkunanathan, et al.
Published: (2025-01-01)

Children’s influence over family food purchases of ultra processed foods: interference of nutritional status
by: Tailane Scapin, et al.
Published: (2015-07-01)

Multiple Factors Related to the Secretion of Glucagon-Like Peptide-1
by: XingChun Wang, et al.
Published: (2015-01-01)

High fructose rewires gut glucose sensing via glucagon-like peptide 2 to impair metabolic regulation in mice
by: Eya Sellami, et al.
Published: (2025-03-01)

Intragastric botulinum toxin injection: a promising alternative for obesity treatment?
by: Hakan Balbaloglu, et al.
Published: (2024-10-01)

The association between 24-h movement behaviours and adiposity among Australian preschoolers: a compositional data analysis
by: Marga Decraene, et al.
Published: (2025-01-01)

Prevalence of digestive diseases in patients with excessive body weight and obesity (<i>according to data of polyclinic department of versatile clinic</i>)
by: I. R. Popova
Published: (2012-09-01)

Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials
by: Haoyang Guo, et al.
Published: (2025-03-01)